Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 2/20 | 0.52 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.50 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.50 |
| ▸ | NAMPT | P43490 | 2/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.46 |
| ▸ | NR1D1 | P20393 | 1/20 | 0.43 |
| ▸ | BCL2 | P10415 | 4/20 | 0.43 |
| ▸ | BAD | Q92934 | 1/20 | 0.43 |
| ▸ | PRMT5 | O14744 | 2/20 | 0.43 |
| ▸ | WDR77 | Q9BQA1 | 2/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | ACE | P12821 | 2/20 | 0.41 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7133564 | 1.00 | OPRD1 (0.52) | OPRD1OPRM1OPRK1NAMPTMEN1 | |
| SCHEMBL31158910 | 1.00 | OPRD1 (0.52) | OPRD1OPRM1OPRK1NAMPTMEN1 | |
| SCHEMBL17572840 | 0.90 | OPRD1 (0.48) | OPRD1OPRM1OPRK1NAMPTMEN1 | |
| SCHEMBL31359949 | 0.88 | MEN1 (0.53) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL31158720 | 0.88 | MEN1 (0.53) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL10207323 | 0.88 | OPRD1 (0.50) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL30299421 | 0.88 | MEN1 (0.53) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL2081318 | 0.88 | MEN1 (0.53) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL3929271 | 0.88 | MEN1 (0.53) | OPRD1NAMPTMEN1KMT2ANR1D1 | |
| SCHEMBL2082826 | 0.88 | MEN1 (0.53) | OPRD1NAMPTMEN1KMT2ANR1D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20080176838-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (DEUTSCHLAND) AG (DE) | 2008-07-24 | — | — | US | disclosed |
| US-20070265301-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070265301-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| US-20070265301-A1 | Dpp-IV Inhibitors | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2007-11-15 | — | — | US | disclosed |
| EP-1828138-A1 | DPP-IV INHIBITORS | Santhera Pharmaceuticals (Schweiz) AG (CH) | 2007-09-05 | — | — | EP | disclosed |
| WO-2005113510-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-01 | — | — | WO | disclosed |
| WO-2005113510-A1 | DPP-IV INHIBITORS | SANTHERA PHARMACEUTICALS (SCHWEIZ) AG (CH) | 2005-12-01 | — | — | WO | disclosed |
| EP-1598341-A1 | DPP-IV inhibitors | Santhera Pharmaceuticals (Deutschland) Aktiengesellschaft (DE) | 2005-11-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070265301-A1 | Dpp-IV Inhibitors | DPP4, DPP8, DPP7 | OPRD1 1112/4885OPRM1 1256/4885OPRK1 1275/4885 |
| US-20080176838-A1 | Dpp-IV Inhibitors | DPP4, DPP9, DPP7 | OPRD1 1303/4885OPRM1 1802/4885OPRK1 1620/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.